drugset
drugset / Trial / NCT04611932

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers

NCT04611932 ↗

Phase 1 Unknown 51 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a randomized, open-label, single dose, 3-period partial replicated crossover study to evaluate the pharmacokinetic profiles and safety of CKD-333 low dose in healthy volunteers under fasting conditions.

Timeline

Start
2020-11-11
Primary completion
2021-03-10
Completion
2021-04-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg —
Subject Atorvastatin Small molecule 10 mg —
Subject Candesartan Unknown 8 mg —

Indications

cardiovascular disorder